DiaDx focuses on the development of alternative analysis systems in oncology based on the use of circulating DNA as a diagnostic tool. DiaDx offers a revolutionary advance for personalized cancer care. The IntPlex(R) test based on a simple blood test developed by DiaDx affords detection and identification of tumor mutations and therefore may replace tests performed on tumor tissues such as biopsy. IntPlex(R) is the unique multimarker test for qualitatively and quantitatively analyzing circulating DNA providing to physicians, patients, pharmaceutical companies and payers real benefits. This technology is functional for solid tumor malignancies (colon, melanoma, prostate cancer, breast cancer, lung cancer ...).